Everything below concerns GW501516. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-26. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
=== Criminal justice and cannabis legalization === In 2014, Newsom was the only statewide politician to endorse California Proposition 47, legislation that recategorized certain nonviolent offenses from felonies to misdemeanors, including shoplifting, grand theft, and receiving stolen property valued at under $950. Voters passed the measure on November 4, 2014. In July 2015, Newsom released the Blue Ribbon Commission on Marijuana Policy's final report, which he had convened with the American Civil Liberties Union of California in 2013. The report's recommendations to regulate cannabis were intended to inform a legalization measure on the November 2016 ballot. Newsom supported the resulting measure, Proposition 64, which legalized cannabis use and cultivation for California state residents who are 21 or older. On February 24, 2017, in response to pro-enforcement statements by White House Press Secretary Sean Spicer, Newsom sent Attorney General Jeff Sessions and President Donald Trump a letter urging them not to increase federal enforcement against recreational cannabis firms opening in California. He wrote: "The government must not strip the legal and publicly supported industry of its business and hand it back to drug cartels and criminals ... Dealers don't card kids.
== Rieske protein family == The homologues of the Rieske proteins include ISP components of cytochrome b6f complex, aromatic-ring-hydroxylating dioxygenases (phthalate dioxygenase, benzene, naphthalene and toluene 1,2-dioxygenases) and arsenite oxidase (EC 1.20.98.1). Comparison of amino acid sequences has revealed the following consensus sequence:
=== Viable analytes === Various compounds, including peptides, dinucleotides, prostaglandins, diquaternary ammonium salts, pesticides, drugs, dyes, and environmental pollutants can be analyzed using thermospray.
Kevin Billings, Honorary Group Captain, 601 (County of London) Squadron, Royal Auxiliary Air Force. For services to the Royal Air Force in the United States of America and the UK. Paul Britton, Chair, Tate Americas Foundation. For services to the arts and to philanthropy. Kevin Burke, Arts Philanthropist and Board Member, BAFTA Hong Kong Advisory Board. For services to charity and to philanthropy. Philip Hugh Davies, Principal, Philip Davies (Heritage and Planning) Ltd. For services to UK and Commonwealth Heritage. Luke Dearden, lately Political Counsellor, UK Delegation to NATO, Brussels, Belgium. For services to British Foreign and Security Policy. Duncan Edwards, Chief Executive Officer, BritishAmerican Business, and Honorary Director, The St. George's Society, New York, United States of America. For services to UK/US Trade relations and to charity. Lieutenant Colonel (Rtd) Michael Edwards, lately Senior Reports Officer, Ceasefire and Transitional Security Arrangements Monitoring and Verification Mechanism, Juba, South Sudan. For services to peace in South Sudan. Brian Hancock, Surgeon, Wythenshaw Hospital; Founding Member and Trustee, Uganda Childbirth Injury Fund. For services to surgery in Sub-Saharan Africa. Susan Hannam, Vice President, CUDECA Hospice Foundation, Spain. For services to palliative care and volunteering services in Spain. Laura Hickey, lately Director Multilateral and Human Rights, Foreign, Commonwealth and Development Office. For services to crisis management and British Foreign Policy.
Sources: en.wikipedia.org
SPPS is limited by reaction yields due to the exponential accumulation of by-products, and typically peptides and proteins in the range of 40 or 50 amino acid residues are pushing the limits of synthetic accessibility of SPPS products as homogeneous molecules of defined chemical structure. Synthetic difficulty also is sequence dependent; typically aggregation-prone sequences such as amyloids are difficult to make. Longer peptides can be accessed by using approaches such as native chemical ligation, where two unprotected synthetic peptides can be covalently condensed in aqueous solution.
=== Approvals === The oral formulations of doxepin are FDATooltip Food and Drug Administration-approved for the treatment of depression and sleep-maintenance insomnia, and its topical formulations are FDA-approved the short-term management for some itchy skin conditions. In Australia and the United Kingdom, the only licensed indications are in the treatment of major depression and pruritus in eczema.
The indictment against Duterte, which was made public on September 22, 2025, accused him of involvement in the murders of 76 people between 2013 and 2018. Fifty-seven of the killings took place during his presidency, and the other 19 occurred during his third term as mayor of Davao City. On October 10, 2025, the ICC rejected a request from Duterte to be released from detention, arguing that he posed a risk of fleeing and would not be willing to return for trial, as well as presenting concerns about potential witness intimidation if he were granted freedom. On January 26, 2026, the ICC declared Duterte fit for trial, overruling efforts by his lawyers to have the charges dismissed on health grounds. Duterte waived his right to appear at any proceedings, with his lawyer Nicholas Kaufman stating that he was not mentally fit to follow the hearing. On April 23, 2026, the Pre-Trial Chamber of the ICC committed Duterte to trial. In May 2026, the ICC Pre-Trial Chamber I denied Duterte's appeal to dismiss the charges. That same month the Trial Chamber III of the ICC set the opening statements in Duterte's trial to begin on November 30, 2026. On September 3, 2026, his defense asked the ICC to verify digital evidence presented by the prosecution, saying that much of the material against Duterte had been taken from open-source and user-generated content from the internet.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.